Supplemental Figure 3 from Clinical Dosing Regimen of Selinexor Maintains Normal Immune Homeostasis and T-cell Effector Function in Mice: Implications for Combination with Immunotherapy

Supplemental Figure 3: Degranulation of effector CD8 T cells is affected by selinexor.</p

Supplemental Figure 1 from Clinical Dosing Regimen of Selinexor Maintains Normal Immune Homeostasis and T-cell Effector Function in Mice: Implications for Combination with Immunotherapy

Supplemental Figure 1: Response to immunization is only modestly affected by selinexor.</p

Supplemental Figure legends from Clinical Dosing Regimen of Selinexor Maintains Normal Immune Homeostasis and T-cell Effector Function in Mice: Implications for Combination with Immunotherapy

Legends for supplemental figures</p

Supplemental Figure 2 from Clinical Dosing Regimen of Selinexor Maintains Normal Immune Homeostasis and T-cell Effector Function in Mice: Implications for Combination with Immunotherapy

Supplemental Figure 2: IFNγ secretion is impaired by selinexor.</p

Supplemental Data from Altered Binding of Tumor Antigenic Peptides to MHC Class I Affects CD8⁺ T Cell–Effector Responses

Supplemental Table and Figures S1 and S2</p

Supplemental Methods from Altered Binding of Tumor Antigenic Peptides to MHC Class I Affects CD8⁺ T Cell–Effector Responses

Supplemental Methods</p

Supplementary Figure S1 from Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1–Specific VHHs

S1. B3 binds to PD-L1 on multiple tumor types.</p

Supplementary Figure Legends from Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1–Specific VHHs

Supplementary Figure Legends from Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1–Specific VHH

Supplementary Figure S3 from Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1–Specific VHHs

S3. Single agent treatment with B3 does not alter B16 growth in vivo.</p

Supplementary Figure S5 from Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1–Specific VHHs

S5. Combination B3-IL2 and A12-IFNγ has additive benefit over either agent alone.</p